Please login to the form below
opicapone
This page shows the latest opicapone news and features for those working in and with pharma, biotech and healthcare.
Neurocrine bags FDA approval for first tardive dyskinesia drug
The company fleshed out its movement disorder pipeline earlier this year by licensing opicapone from Portuguese drug maker BIAL.
Latest news
-
EC approves Bial’s Parkinson’s disease therapy
Manufactured by Bial, Ongentys (opicapone) is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adults with Parkinson's and end-of-dose motor fluctuations who cannot ... Opicapone is a third-generation
-
Chasing the cure for Parkinson's disease
Opicapone (Bial) is a COMT inhibitor in phase III development in various European countries for the treatment of idiopathic Parkinson's. ... Bial plans to develop opicapone to be administered in combination with levodopa/carbidopa or
EC approves Bial’s Parkinson’s disease therapy
Chasing the cure for Parkinson's disease
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).
Deal Watch February 2017
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Events Executive
-
Depending on Experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
No results were found
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
